SML2655

Reparixin

≥98% (HPLC)

• Synonym(e): αR-methyl-4-(2-methylpropyl)-N-(methylsulfonyl)-benzeneacetamide, (R)-(-)-N-2-[(4-Isobutylphenyl)propionyl]methanesulfonamide, DF 1681Y, Repertaxin
• Empirische Formel (Hill-System): C₁₄H₂₁NO₃S
• CAS-Nummer: 266359-83-5
• Molekulargewicht: 283.39
• UNSPSC Code: 51111800
• NACRES: NA.77
• MDL number: MFCD18633292
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D -80 to -90°, c = 1.0 in ethanol
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: [S](=O)(=O)(NC(=O)C(C)c1ccc(cc1)CC(C)C)C
• InChI: 1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)
• InChI key: KQDRVXQXKZXMHP-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

Noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2

Reparixin is a noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2 with IC50 values of 1 nM for CXCR1 and 100 nM for CXCR2. It is believed to prevent receptor signaling by locking CXCR1/R2 in an inactive conformation. Reparixin has been studied to prevent ischaemia-reperfusion injury and inflammation and is clinical trials for triple negative breast cancer and to prevent injury occurring after pancreatic islet transplantation.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable